Zentiva Expands CHC Portfolio with Acquisition of Five Heritage Brands from Aboca

Zentiva's acquisition of five heritage brands from Aboca, including Propol2 EMF, Ruscoven, and Serenil, strengthens its CHC portfolio and market position. The move aligns with the growing consumer demand for natural products and is set to be finalized on 30 June 2025. Steffen Saltofte, CEO of Zentiva, highlights the strategic fit between Zentiva's consumer healthcare reach and Aboca's plant-based science expertise.